GlassScriptLumoxiti
Payments companies reported to CMS as associated with Lumoxiti. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Lumoxiti, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Lumoxiti
These are the largest totals companies reported as associated with Lumoxiti. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Javid Moslehi | San Francisco, CA | Cardiovascular Disease | $15,285.50 |
| Preetesh Jain | Houston, TX | Internal Medicine | $6,165.00 |
| Emily Tomasulo | Philadelphia, PA | Hematology & Oncology | $4,795.00 |
| Maria Mejias | Memphis, TN | Pediatric Infectious Diseases | $4,200.00 |
| Moshe Levy | Dallas, TX | Medical Oncology | $4,110.00 |
| Amitkumar Mehta | Birmingham, AL | Hematology & Oncology | $4,110.00 |
| Anthony Mato | Ithaca, NY | Medical Oncology | $3,425.00 |
| Zhuoyan Li | Baltimore, MD | Hematology & Oncology | $2,497.50 |
| Solly Chedid | Pascagoula, MS | Hematology & Oncology | $2,397.50 |
| Caleb Scheckel | Tulsa, OK | Hematology & Oncology | $2,397.50 |
Prescribed Lumoxiti?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.